Atopic Dermatitis: Global Drug Forecast and Market Analysis to 2027

Atopic dermatitis is a widespread chronic inflammatory skin condition that can affect patients of all ages and is the result of a complex interplay of environmental, immunological, genetic, and pharmacologic factors. The atopic dermatitis market has historically remained stagnant and the pipeline for drugs in late-stage development was lacking, but recent developments have reignited interest in the treatment of the disease, especially as the estimated drug-treated population may grow to 24,000,000 people over the next decade.

In March 2017, Regeneron/Sanofi gained approval for Dupixent (dupilumab), the first-in-class interleukin (IL)-4 receptor inhibitor that has set a new gold standard in the treatment of atopic dermatitis. Moreover, a highly competitive and genericized topical market has pushed other pharmaceutical companies to develop their own systemic treatments, with a new class of therapies in development, Janus kinase (JAK) inhibitors, two of which have already been granted Breakthrough Therapy designation by the FDA. As a result, the atopic dermatitis market is set to become much more dynamic, with widening appreciation that atopic dermatitis is a highly variable disease and that not every patient will react in the same way to the same therapy. With existing unmet needs in the topical landscape for treatments that do not have side effects and for better understanding the pathophysiology and etiology of the disease, atopic dermatitis represents an attractive dermatology sector for drug developers. In turn, this will fuel commercial interest in this market.

GlobalData estimates that sales of drugs in the atopic dermatitis market were approximately $6.4B in 2017 in the 7MM. The US was the largest market, with approximately $5.1B in drug sales, which represented 80% of the total atopic dermatitis market. The 5EU market contributed $1.1B in sales and Japan contributed sales of $202M in 2017.

Global sales in the atopic dermatitis market are expected to grow to $18.3B by 2027, at a Compound Annual Growth Rate (CAGR) of 11.1% from 2017-2027. GlobalData forecasts the US to grow to $13.6B (74.5% of global sales), the 5EU to grow to $4B (21.7% of global sales), and Japan to grow to $693M (3.8% of global sales) over the next 10 years.

Key Questions Answered

The projected entry of pipeline agents such as the Interleukin inhibitors and the JAK inhibitors during the forecast period is expected to spur intense growth within the atopic dermatitis market. How do products compete against each other? Which of these drugs will have the highest peak sales, and why?

Key Opinion Leaders (KOLs) interviewed by GlobalData have indicated that there are considerably high unmet needs within the atopic dermatitis indication. What are the main unmet needs in this market? How can the pharmaceutical industry address these needs? To what degree will the therapies under development fulfill these unmet needs?

The atopic dermatitis market is likely to remain a dynamic, growing space throughout the forecast period and beyond. Which companies are set to be major players in atopic dermatitis during the forecast period?

Scope

Overview of atopic dermatitis including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

Annualized atopic dermatitis therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2017 and forecast for ten years to 2027.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the atopic dermatitis therapeutics market.

Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.

Analysis of the current and future market competition in the global atopic dermatitis therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global atopic dermatitis therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global atopic dermatitis therapeutics market in future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Track drug sales in the global atopic dermatitis therapeutics market from 2017-2027.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Companies mentioned

Sanofi

Regeneron

LEO Pharma

Pfizer

AbbVie

Dermira

Eli Lilly

Galderma

Incyte

Bausch Health

Meda

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Atopic Dermatitis: Executive Summary

2.1 Atopic Dermatitis Market to Experience Strong Growth from 20172027

2.2 Late-Stage Pipeline Product Launches Will Result in New Players Establishing Themselves

2.3 Persistent Unmet Needs Will Be Addressed Over the Forecast Period

2.4 Interleukin Inhibitors and Janus Kinase Inhibitors Dominate the Atopic Dermatitis Pipeline

2.5 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.1.1 Etiology

4.1.2 Pathophysiology

4.2 Classification or Staging Systems

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.4 Forecast Methodology

5.4.1 Sources

5.4.2 Forecast Assumptions and Methods – Population

5.4.3 Forecast Assumptions and Methods – One-Year Total and Diagnosed Prevalent Cases of Atopic Dermatitis

5.4.4 Forecast Assumptions and Methods – One-Year Total Prevalent Cases of Atopic Dermatitis by Severity

5.4.5 Forecast Assumptions and Methods – One-Year Diagnosed Prevalent Cases of Atopic Dermatitis by Severity

5.5 Epidemiological Forecast for Atopic Dermatitis (20172027)

5.5.1 One-Year Total Prevalent Cases of Atopic Dermatitis

5.5.2 Age-Specific One-Year Total Prevalent Cases of Atopic Dermatitis

5.5.3 Sex-Specific One-Year Total Prevalent Cases of Atopic Dermatitis

5.5.4 One-Year Total Prevalent Cases of Atopic Dermatitis by Severity

5.5.5 One-Year Diagnosed Prevalent Cases of Atopic Dermatitis

5.5.6 Age-Specific One-Year Diagnosed Prevalent Cases of Atopic Dermatitis

5.5.7 Sex-Specific One-Year Diagnosed Prevalent Cases of Atopic Dermatitis

5.5.8 One-Year Diagnosed Prevalent Cases of Atopic Dermatitis by Severity

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Limitations of the Analysis

5.6.3 Strengths of the Analysis

6 Disease Management

6.1 Diagnosis and Treatment Overview

6.2 US

6.3 5EU

6.4 Japan

7 Competitive Assessment

7.1 Overview

8 Unmet Needs and Opportunity Assessment

8.1 Overview

8.2 Topical Treatments Without Side Effects

8.3 A Drug that Effectively Controls Patients’ Pruritus

8.4 Addressing Heterogeneity in the Pathophysiology of Atopic Dermatitis

8.5 Improved Patient Compliance and Education

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

10 Current and Future Players

10.1 Overview

10.2 Trends in Corporate Strategy

10.3 Company Profiles

10.3.1 LEO Pharma

10.3.2 Pfizer

10.3.3 Regeneron

10.3.4 AbbVie

10.3.5 Dermira

10.3.6 Eli Lilly

10.3.7 Galderma

10.3.8 Incyte

10.4 Other Players

11 Market Outlook

11.1 Global Markets

11.1.1 Forecast

11.1.2 Drivers and Barriers – Global Issues

11.2 US

11.2.1 Forecast

11.2.2 Key Events

11.2.3 Drivers and Barriers

11.3 5EU

11.3.1 Forecast

11.3.2 Key Events

11.3.3 Drivers and Barriers

11.4 Japan

11.4.1 Forecast

11.4.2 Key Events

11.4.3 Drivers and Barriers

12 Appendix

12.1 Bibliography

12.2 Abbreviations

12.3 Methodology

12.3.1 Forecasting Methodology

12.3.2 Diagnosed Patients

12.3.3 Percent Drug-Treated Patients

12.3.4 Drugs Included in Each Therapeutic Class

12.3.5 Launch and Patent Expiry Dates

12.3.6 General Pricing Assumptions

12.3.7 Individual Drug Assumptions

12.3.8 Generic Erosion

12.3.9 Pricing of Pipeline Agents

12.4 Primary Research – Key Opinion Leaders and Payers Interviewed for This Report

12.4.1 Key Opinion Leaders

12.4.2 Payers

12.5 Primary Research – Prescriber Survey

12.6 About the Authors

12.6.1 Analyst

12.6.2 Reviewer

12.6.3 Therapy Area Director

12.6.4 Epidemiologist

12.6.5 Managing Epidemiologists

12.6.6 Global Director of Therapy Analysis and Epidemiology

12.6.7 Global Head and EVP of Healthcare Operations and Strategy

12.7 About GlobalData

12.8 Contact Us

12.9 Disclaimer

List of Tables

Table 1: Atopic Dermatitis: Key Metrics in the 7MM

Table 2: Risk Factors and Comorbid Conditions Associated with Atopic Dermatitis

Table 3: Treatment Guidelines for Atopic Dermatitis

Table 4: Country Profile – US

Table 5: Country Profile – 5EU

Table 6: Country Profile – Japan

Table 7: Leading Treatments for Atopic Dermatitis, 2017

Table 8: Comparison of Therapeutic Classes in the Development for Atopic Dermatitis, 2017–2027

Table 9: LEO Pharma’s Atopic Dermatitis Portfolio Assessment, 2018

Table 10: Pfizer’s Atopic Dermatitis Portfolio Assessment, 2018

Table 11: Regeneron’s Atopic Dermatitis Portfolio Assessment, 2018

Table 12: AbbVie’s Atopic Dermatitis Portfolio Assessment, 2018

Table 13: Dermira’s Atopic Dermatitis Portfolio Assessment, 2018

Table 14: Eli Lilly’s Atopic Dermatitis Portfolio Assessment, 2018

Table 15: Galderma’s Atopic Dermatitis Portfolio Assessment, 2018

Table 16: Incyte’s Disease Portfolio Assessment, 2018

Table 17: Atopic Dermatitis Market – Global Drivers and Barriers, 2017–2027

Table 18: Key Events Impacting Sales for Atopic Dermatitis in the US, 2017–2027

Table 19: Atopic Dermatitis Market – Drivers and Barriers in the US, 2017–2027

Table 20: Key Events Impacting Sales for Atopic Dermatitis in the 5EU, 2017–2027

Table 21: Atopic Dermatitis Market – Drivers and Barriers in the 5EU, 2017–2027

Table 22: Key Events Impacting Sales for Atopic Dermatitis in Japan, 2017–2027

Table 23: Atopic Dermatitis Market – Global Drivers and Barriers in Japan, 2017–2027

Table 24: Key Projected Launch Dates for Atopic Dermatitis

Table 25: Key Historical and Projected Patent Expiry Dates for Atopic Dermatitis

Table 26: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

Figure 1: Global Sales Forecast by Country for Atopic Dermatitis in 2017 and 2027

Figure 2: Analysis of the Company Portfolio Gap in Atopic Dermatitis During the Forecast Period

Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of Atopic Dermatitis During the Forecast Period

Figure 4: Major Drug Targets for Atopic Dermatitis Treatment

Figure 5: 7MM, Age-Standardized One-Year Total Prevalence of Atopic Dermatitis (%), Both Sexes, All Ages, 2017

Figure 6: 7MM, Sources Used and Not Used to Forecast the One-Year Total and Diagnosed Prevalent Cases of Atopic Dermatitis

Figure 7: 7MM, Sources Used to Forecast the One-Year Total Prevalence by Severity of Atopic Dermatitis

Figure 8: 7MM, Sources Used to Forecast the One-Year Diagnosed Prevalent Cases by Severity of Atopic Dermatitis

Figure 9: 7MM, One-Year Total Prevalent Cases of Atopic Dermatitis, Both Sexes, All Ages, N, 2017

Figure 10: 7MM, Age-Specific One-Year Total Prevalent Cases of Atopic Dermatitis, Both Sexes, All Ages, N, 2017

Figure 11: 7MM, Sex-Specific One-Year Total Prevalent Cases of Atopic Dermatitis, All Ages, N, 2017

Figure 12: 7MM, One-Year Total Prevalent Cases of Atopic Dermatitis by Severity, Both Sexes, All Ages, N, 2017

Figure 13: 7MM, One-Year Diagnosed Prevalent Cases of Atopic Dermatitis, Both Sexes, All Ages, N, 2017

Figure 14: 7MM, Age-Specific One-Year Diagnosed Prevalent Cases of Atopic Dermatitis, Both Sexes, All Ages, N, 2017

Figure 15: 7MM, Sex-Specific One-Year Diagnosed Prevalent Cases of Atopic Dermatitis, All Ages, N, 2017

Figure 16: 7MM, One-Year Diagnosed Prevalent Cases by Severity of Atopic Dermatitis, Both Sexes, All Ages, N, 2017

Figure 17: Flowchart of the Diagnosis and Management of Atopic Dermatitis

Figure 18: Unmet Needs and Opportunities in Atopic Dermatitis

Figure 19: Overview of the Development Pipeline in Atopic Dermatitis

Figure 20: Key Phase II/III Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for Atopic Dermatitis in the 7MM During the Forecast Period

Figure 21: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of Atopic Dermatitis During the Forecast Period

Figure 22: Analysis of the Company Portfolio Gap in Atopic Dermatitis During the Forecast Period

Figure 23: Global (7MM) Sales Forecast for Atopic Dermatitis by Country in 2017 and 2027

Figure 24: Sales Forecast for Atopic Dermatitis by Class in the US in 2017 and 2027

Figure 25: Sales Forecast for Atopic Dermatitis in the 5EU by Class in 2017 and 2027

Figure 26: Sales Forecast for Atopic Dermatitis by Class in Japan in 2017 and 2027

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Join our mailing list

Saved reports